Tag: BioNTech

Investors are bracing for a pivotal fortnight at BioNTech SE, with a first-quarter earnings report and a consequential shareholder meeting ...

All eyes are on May 5th. When BioNTech reports its first-quarter earnings, investors will scrutinize more than just revenue from ...

Positive clinical results for a late-stage cancer drug candidate have strengthened BioNTech's strategic pivot away from its pandemic-era business. The ...

Market confidence in BioNTech is being tested as analysts from prominent firms revise their outlooks downward. Leerink Partners has taken ...

As BioNTech navigates a pivotal transition away from its pandemic-era revenue, the company is asking its shareholders to approve a ...

BioNTech is methodically moving beyond its pandemic legacy. A series of recent strategic decisions—from facility closures and halted trials to ...

Investors in BioNTech are assessing a new regulatory challenge that could impact the commercial prospects of its COVID-19 vaccine, Comirnaty, ...

A Belgian court has delivered a substantial financial and legal win for BioNTech and its partner Pfizer. The ruling, issued ...

In a year marked by significant revenue declines for major players in the mRNA and COVID-19 vaccine space, BioNTech SE ...

BioNTech's stock has faced significant headwinds from founder transitions and subdued financial forecasts. However, developments within its research pipeline offer ...